<DOC>
	<DOCNO>NCT01711840</DOCNO>
	<brief_summary>The purpose investigation confirm safety patient receive Symbicort Turbuhaler maintenance reliever therapy ( Symbicort SMART ) post-marketing actual use .</brief_summary>
	<brief_title>Clinical Experience Investigation Symbicort Turbuhaler Maintenance Therapy Reliever Therapy</brief_title>
	<detailed_description>Symbicort Turbuhaler 30/60 Clinical Experience Investigation treatment Symbicort maintenance therapy need response symptom</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Budesonide , Formoterol Fumarate Drug Combination</mesh_term>
	<criteria>Patients receive Symbicort Turbuhaler maintenance reliever therapy first time due 'bronchial asthma ' , possibly require asneeded inhalation observation period</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Bronchial asthma</keyword>
	<keyword>Symbicort Turbuhaler</keyword>
</DOC>